Advertisement

International Journal of Hematology

, Volume 83, Issue 3, pp 275–276 | Cite as

Intensive Immunosuppression Therapy for Aplastic Anemia Associated with Dyskeratosis Congenita

  • Mohamad M. Al-Rahawan
  • Neelam Giri
  • Blanche P. Alter
Letter to the Editor

Keywords

Telomere Length Aplastic Anemia Antithymocyte Globulin Bone Marrow Failure Dyskeratosis Congenita 

References

  1. 1.
    Comoli P, Basso S, Huanga GC. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a case. Int J Hematol. 2005;82:35–37.CrossRefGoogle Scholar
  2. 2.
    Drachtman RA, Alter BP. Dyskeratosis congenita: Clinical and genetic heterogeneity. Report of a new case and review of the literature. Am J Pediatr Hematol Oncol. 1992;14:297–304.CrossRefGoogle Scholar
  3. 3.
    Marrone A, Dokal I. Dyskeratosis congenita: molecular insights into telomerase function, ageing and cancer. Expert Rev Mol Med. 2004;6:1–23.CrossRefGoogle Scholar
  4. 4.
    Alter BP, Baerlocher G, Savage S, et al. Diagnosis of dyskeratosis congenita by telomere length. Pediatr Blood Cancer. 2005;44:537.Google Scholar
  5. 5.
    Baerlocher GM, Mak J, Tien T, Lansdorp PM. Telomere length measurement by fluorescence in situ hybridization and flow cytometry: tips and pitfalls. Cytometry. 2002;47:89–99.CrossRefGoogle Scholar
  6. 6.
    Marsh JC. Management of acquired aplastic anaemia. Blood Rev. 2005;19:143–151.CrossRefGoogle Scholar
  7. 7.
    Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, and the German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–1242.CrossRefGoogle Scholar
  8. 8.
    Alter BP. Inherited bone marrow failure syndromes. In: Nathan DG, Orkin SH, Look AT, Ginsburg D, eds. Nathan and Oski’s Hematology of Infancy and Childhood. 6th ed. Philadelphia, PA: WB Saunders, 2003:280–365.Google Scholar
  9. 9.
    Alter BP, Gardner FH, Hall RE. Treatment of dyskeratosis congenita with granulocyte colony-stimulating factor and erythropoietin. Br J Haematol. 1997;97:309–311.CrossRefGoogle Scholar
  10. 10.
    Gungor T, Corbacioglu S, Storb R, Seger RA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita. Bone Marrow Transplant. 2003;31:407–410.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Mohamad M. Al-Rahawan
    • 1
    • 2
  • Neelam Giri
    • 1
  • Blanche P. Alter
    • 1
  1. 1.MPH, Clinical Genetics Branch, Division of Cancer Epidemiology and GeneticsNational Cancer InstituteRockvilleUSA
  2. 2.Children’s National Medical Center, Pediatric Hematology/Oncology, Center for Cancer and Blood DisordersThe George Washington University Medical CenterWashington, DCUSA

Personalised recommendations